Barros Pereira Isabel, Carvalho Rui M, Graça Luís M
Clínica Universitária de Obstetrícia e Ginecologia, CHLN, Hospital Universitário de Santa Maria, Faculdade de Medicina da Universidade de Lisboa, CAM - Centro Académico de Medicina de Lisboa, Lisbon, Portugal.
Clínica Universitária de Obstetrícia e Ginecologia, CHLN, Hospital Universitário de Santa Maria, Faculdade de Medicina da Universidade de Lisboa, CAM - Centro Académico de Medicina de Lisboa, Lisbon, Portugal.
Eur J Obstet Gynecol Reprod Biol. 2015 Feb;185:33-5. doi: 10.1016/j.ejogrb.2014.11.025. Epub 2014 Nov 29.
Etonogestrel subdermal implant is a highly effective, reversible and safe form of contraception. Immediate placement during abortion visit could increase contraception use in women at high risk for unintended pregnancy. Our purpose was to evaluate patient acceptability, user continuation rate and efficacy of medical termination of pregnancy when the implant is inserted during medical termination of pregnancy.
Prospective observational study comparing patients who chose the subdermal implant for post-abortion contraception, inserted at the time of administration of mifepristone, with patients who chose delayed placement after the termination was complete.
After contraceptive counseling 119 women chose the implant as their post-abortion contraceptive method. In the intra-abortion implant insertion group the user continuation rate after 6 months was 73.7% (42/57). In the delayed placement group 59.7% (37/62) missed the follow-up after abortion visit, 24.2% (15/62) chose another method and only 16.1% (10/62) had the implant inserted. The efficacy of medical termination was 96.5% in the group of intra-abortion implant insertion and 98.4% in the delayed placement group.
Intra-abortion subdermal implant insertion significantly increases the likelihood of effective long-acting contraception use following abortion. The efficacy of medical termination was not significantly changed by intra-abortion implant insertion.
依托孕烯皮下埋植剂是一种高效、可逆且安全的避孕方式。在流产就诊时即刻放置该埋植剂可提高意外妊娠高危女性的避孕措施使用率。我们的目的是评估在药物流产期间植入皮下埋植剂时患者的可接受性、使用者持续率以及药物流产的效果。
前瞻性观察性研究，比较在服用米非司酮时选择皮下埋植剂用于流产后避孕的患者，与在流产结束后选择延迟放置的患者。
经过避孕咨询后，119名女性选择皮下埋植剂作为她们的流产后避孕方法。在流产时植入皮下埋植剂组中，6个月后的使用者持续率为73.7%（42/57）。在延迟放置组中，59.7%（37/62）在流产就诊后未进行随访，24.2%（15/62）选择了其他方法，只有16.1%（10/62）植入了皮下埋植剂。流产时植入皮下埋植剂组的药物流产成功率为96.5%，延迟放置组为98.4%。
流产时皮下埋植剂植入显著增加了流产后有效使用长效避孕措施的可能性。流产时植入皮下埋植剂并未显著改变药物流产的效果。
